Strikingly, the mutations are single amino acid substitutions at an arginine residue in the active site of the enzyme (e.g., R132 for IDH1 and R172 in IDH2 in gliomas or R140 for IDH2 in AML). This evidence concerns the gene IDH2 and central nervous system cancer.